|
2019 Conference Publication Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progressionDe Brouwer, E., Peeters, L., Becker, T., Altintas, A., Soysal, A., Van Wijmeersch, B., Boz, C., Oreja-Guevara, C., Gobbi, C., Solaro, C., Ramo, C., Spitaleri, D. L., Maimone, D., Aguera-Morales, E., Cartechini, E., Butler, E., Havrdova, E., Patti, F., Granella, F., Grand'Maison, F., Moore, F., Verheul, F., Iuliano, G., Butzkueven, H., Lechner-Scott, J., Kuhle, J., Sanchez Menoyo, J. L., Rojas, J. I., Prevost, J. ... Moreau, Y. (2019). Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Journal Article Risk of secondary progressive multiple sclerosis: A longitudinal studyFambiatos, Adam, Jokubaitis, Vilija, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Bergamaschi, Roberto, Van Pesch, Vincent, Ozakbas, Serkan, Granella, Franco, Turkoglu, Recai, Iuliano, Gerardo, Spitaleri, Daniele, McCombe, Pamela, Solaro, Claudio ... Kalincik, Tomas (2019). Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 26 (1) 1352458519868990, 135245851986899-90. doi: 10.1177/1352458519868990 |
|
2019 Journal Article Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximabChan, Fiona, Swayne, Andrew, Gillis, David, Walsh, Michael, Henderson, Robert D., McCombe, Pamela A., Wong, Richard C. and Blum, Stefan (2019). Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. Journal of Neurology, Neurosurgery and Psychiatry, 90 (8), 1-2. doi: 10.1136/jnnp-2018-319410 |
|
2019 Journal Article Interaction of neurotransmitters and neurochemicals with lymphocytesKerage, Daniel, Sloan, Erica K., Mattarollo, Stephen R. and McCombe, Pamela A. (2019). Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology, 332, 99-111. doi: 10.1016/j.jneuroim.2019.04.006 |
|
2019 Conference Publication Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study). 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY. |
|
2019 Conference Publication Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC studySprenger, T., Lebrun-Frenay, C., Vermersch, P., Park, M. S., Chinchilla, D., McCombe, P., Lincoln, J., Bergsland, N., Dwyer, M., Kappos, L., Cavalier, S., Roesch, N., Guce, M., Poole, E. and Zivadinov, R. (2019). Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study. 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY. |
|
2019 Journal Article Gut microbiota in ALS: possible role in pathogenesis?McCombe, Pamela A., Henderson, Robert D., Lee, Aven, Lee, John D., Woodruff, Trent M., Restuadi, Restuadi, McRae, Allan, Wray, Naomi R., Ngo, Shyuan and Steyn, Frederik J. (2019). Gut microbiota in ALS: possible role in pathogenesis?. Expert Review of Neurotherapeutics, 19 (9), 1-21. doi: 10.1080/14737175.2019.1623026 |
|
2019 Journal Article Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosisNgo, Shyuan T., Van Eijk, Ruben P. A., Chachay, V. , Van Den Berg, Leonard H., Mccombe, Pamela A., Henderson, Robert D. and Steyn, Frederik J. (2019). Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 20 (7-8), 1-9. doi: 10.1080/21678421.2019.1621346 |
|
2019 Journal Article Women who contributed to past research in multiple sclerosisMcCombe, Pamela A. (2019). Women who contributed to past research in multiple sclerosis. Multiple Sclerosis Journal, 25 (11), 1352458519846101-1443. doi: 10.1177/1352458519846101 |
|
2019 Conference Publication Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorderKunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse ... Kalincik, Tomas (2019). Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, United States, 4-10 May 2019. Philadelphia, PA, United States: Wolters Kluwer Health. |
|
2019 Conference Publication Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC StudySprenger, Till, Lebrun-Frenay, Christine, Vermersch, Patrick, Park, Min Su, Chinchilla, Dennis, McCombe, Pamela, Lincoln, John, Kappos, Ludwig, Bergsland, Niels, Dwyer, Michael, Cavalier, Steven, Roesch, Nora, Somera-Molina, Kathleen, Poole, Elizabeth and Zivadinov, Robert (2019). Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p3.2-037 |
|
2019 Journal Article Cumulative influence of parity-related genomic changes in multiple sclerosisMehta, Divya, Wani, Shivangi, Wallace, Leanne, Henders, Anjali K., Wray, Naomi R. and McCombe, Pamela A. (2019). Cumulative influence of parity-related genomic changes in multiple sclerosis. Journal of Neuroimmunology, 328, 38-49. doi: 10.1016/j.jneuroim.2018.12.004 |
|
2019 Journal Article Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imagingAlruwaili, Ashwag R., Pannek, Kerstin, Henderson, Robert D., Gray, Marcus, Kurniawan, Nyoman D. and McCombe, Pamela A. (2019). Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imaging. BMC Medical Imaging, 19 (1) 19, 19. doi: 10.1186/s12880-019-0319-3 |
|
2019 Journal Article Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort studyNguyen, Ai-Lan, Havrdova, Eva Kubala, Horakova, Dana, Izquierdo, Guillermo, Kalincik, Tomas, van der Walt, Anneke, Terzi, Murat, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Boz, Cavit, Sola, Patrizia, Ferraro, Diana, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Barnett, Michael, Grand'Maison, Francois, Grammond, Pierre, Ramo-Tello, Cristina, Turkoglu, Recai, McCombe, Pamela, Pucci, Eugenio, Trojano, Maria, Granella, Franco, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Oreja-Guevara, Celia ... Jokubaitis, Vilija (2019). Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Multiple Sclerosis and Related Disorders, 28, 235-243. doi: 10.1016/j.msard.2019.01.003 |
|
2019 Journal Article Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosisBrown, J. William L., Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessandra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francois, Terzi, Murat, Lechner-Scott, Jeannette, Flechter, Schlomo, Slee, Mark, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Willis, Mark, Rice, Claire ... Robertson, Neil (2019). Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA - Journal of the American Medical Association, 321 (2), 175-187. doi: 10.1001/jama.2018.20588 |
|
2019 Conference Publication Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Journal Article Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisKalincik, Tomas, Kubala Havrdova, Eva, Horakova, Dana, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeannette, Boz, Cavit, Grand'Maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Trojano, Maria, Bergamaschi, Roberto, Pucci, Eugenio, Turkoglu, Recai, McCombe, Pamela A, Pesch, Vincent Van, Van Wijmeersch, Bart, Solaro, Claudio ... Butzkueven, Helmut (2019). Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 90 (4), 458-468. doi: 10.1136/jnnp-2018-319831 |
|
2019 Conference Publication Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 yearsCelius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
